While a connection has been found between psoriasis and cardiovascular disease, a recent study has found no link between another skin disease, atopic dermatitis, and cardiovascular disease.
An association between the skin condition, eczema, and an increased risk of cardiovascular disease cannot be found, according to a study.
In a study recently published in the British Journal of Dermatology, Aaron Drucker, MD, FRCPC, an assistant professor of dermatology at the Warren Alpert Medical School of Brown University and a physician with the Lifespan Physicians Group, and his team investigated records of 258,119 people, 30 to 74 years old, in the Canadian Partnership for Tomorrow Project.
Originally, Drucker created a hypothesis that suggested that people with atopic dermatitis (AD), a form of eczema, were more likely to have cardiovascular issues. However, the study revealed the absence of a link between AD and cardiovascular disease.
The study found a 0.79 times reduced risk of stroke, 0.87 times reduced risk of hypertension, 0.78 times reduced risk of diabetes, and a 0.97 times reduced risk of heart attack.
“It’s important to make this clear so it doesn’t get misinterpreted: Even though we found lower rates of these outcomes with atopic dermatitis, we are not interpreting that as atopic dermatitis decreasing the risk,” said Drucker.
The common idea that AD and cardiovascular disease are related is typically assumed because of the connection that has been identified between psoriasis, another skin condition, and cardiovascular disease, the study noted. Despite the similarities between psoriasis and AD, the 2 skin conditions vary at the molecular level.
“In response to the increased risk of cardiovascular disease discovered for psoriasis, clinicians and psoriasis patients have been encouraged to more actively screen for and manage cardiovascular disease,” Drucker points out. “It appears that similar measures may not be warranted for atopic dermatitis.”
The study concluded that while AD is not necessarily associated with cardiovascular disease, Drucker is looking to investigate a possible connection between AD severity and cardiovascular disease.
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer
October 22nd 2024By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for patients with advanced epithelial ovarian cancer, overtaking primary cytoreductive surgery.
Read More